See more : Gowest Gold Ltd. (GWSAF) Income Statement Analysis – Financial Results
Complete financial analysis of AbbVie Inc. (4AB.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AbbVie Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- PT Aneka Tambang Tbk (ANTM.JK) Income Statement Analysis – Financial Results
- Monaker Group, Inc. (MKGI) Income Statement Analysis – Financial Results
- Anaergia Inc. (ANRG.TO) Income Statement Analysis – Financial Results
- Financière de Tubize SA (TUB.BR) Income Statement Analysis – Financial Results
- Gensol Engineering Limited (GENSOL.NS) Income Statement Analysis – Financial Results
AbbVie Inc. (4AB.DE)
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.32B | 58.05B | 56.20B | 45.80B | 33.27B | 32.75B | 28.22B | 25.64B | 22.86B | 19.96B | 18.79B | 18.38B | 17.44B | 15.64B | 14.21B |
| Cost of Revenue | 16.73B | 17.41B | 17.45B | 15.39B | 7.44B | 7.72B | 7.04B | 5.83B | 4.50B | 4.43B | 4.58B | 4.51B | 4.64B | 4.29B | 4.06B |
| Gross Profit | 37.59B | 40.64B | 38.75B | 30.42B | 25.83B | 25.04B | 21.18B | 19.81B | 18.36B | 15.53B | 14.21B | 13.87B | 12.80B | 11.35B | 10.16B |
| Gross Profit Ratio | 69.21% | 70.00% | 68.96% | 66.41% | 77.64% | 76.44% | 75.05% | 77.25% | 80.31% | 77.83% | 75.62% | 75.47% | 73.40% | 72.55% | 71.46% |
| Research & Development | 8.45B | 6.51B | 7.08B | 6.56B | 6.41B | 10.33B | 4.98B | 4.37B | 4.29B | 3.30B | 2.86B | 2.78B | 2.62B | 2.50B | 1.71B |
| General & Administrative | 10.70B | 13.26B | 10.25B | 9.50B | 5.84B | 7.40B | 6.28B | 5.86B | 6.39B | 7.72B | 5.35B | 4.99B | 5.89B | 3.82B | 3.35B |
| Selling & Marketing | 2.20B | 2.00B | 2.10B | 1.80B | 1.10B | 1.10B | 846.00M | 764.00M | 704.00M | 665.00M | 626.00M | 506.00M | 0.00 | 0.00 | 0.00 |
| SG&A | 12.87B | 15.26B | 12.35B | 11.30B | 6.94B | 7.40B | 6.28B | 5.86B | 6.39B | 7.72B | 5.35B | 4.99B | 5.89B | 3.82B | 3.35B |
| Other Expenses | 3.51B | 56.00M | 432.00M | -5.61B | -890.00M | -18.00M | -513.00M | -232.00M | -13.00M | 27.00M | 1.00M | 9.00M | 0.00 | 61.00M | 0.00 |
| Operating Expenses | 24.84B | 21.83B | 19.87B | 17.86B | 12.46B | 18.23B | 11.26B | 10.22B | 10.67B | 11.77B | 8.21B | 7.77B | 8.51B | 6.32B | 5.06B |
| Cost & Expenses | 41.56B | 39.24B | 37.31B | 33.24B | 19.90B | 25.95B | 18.30B | 16.05B | 15.17B | 16.20B | 12.79B | 12.28B | 13.15B | 10.61B | 9.11B |
| Interest Income | 540.00M | 186.00M | 39.00M | 174.00M | 275.00M | 204.00M | 146.00M | 82.00M | 33.00M | 38.00M | 21.00M | 20.00M | 20.00M | 28.00M | 0.00 |
| Interest Expense | 2.22B | 2.23B | 2.38B | 2.28B | 1.51B | 1.14B | 1.00B | 965.00M | 686.00M | 391.00M | 278.00M | 104.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.70B | 8.47B | 8.52B | 6.47B | 2.02B | 1.77B | 1.50B | 1.19B | 836.00M | 786.00M | 897.00M | 1.15B | 1.27B | 1.18B | 697.49M |
| EBITDA | 26.36B | 31.42B | 28.28B | 21.15B | 16.26B | 13.69B | 11.77B | 10.81B | 9.69B | 6.29B | 6.91B | 6.98B | 4.94B | 6.02B | 5.80B |
| EBITDA Ratio | 48.53% | 33.86% | 29.16% | 15.17% | 41.47% | 22.15% | 37.55% | 39.34% | 35.13% | 24.01% | 34.03% | 39.63% | 35.49% | 40.31% | 34.83% |
| Operating Income | 12.76B | 11.19B | 7.87B | 476.00M | 12.98B | 6.38B | 9.59B | 9.38B | 7.54B | 3.41B | 5.66B | 5.82B | 3.62B | 4.72B | 4.93B |
| Operating Income Ratio | 23.49% | 19.28% | 14.00% | 1.04% | 39.03% | 19.49% | 33.99% | 36.60% | 32.97% | 17.09% | 30.14% | 31.65% | 20.76% | 30.16% | 34.70% |
| Total Other Income/Expenses | -6.51B | 2.29B | 5.12B | 2.92B | -4.56B | -1.19B | -1.82B | -1.46B | -892.00M | -1.04B | -332.00M | -92.00M | 48.00M | 119.00M | 1.02B |
| Income Before Tax | 6.25B | 13.48B | 12.99B | 3.40B | 8.43B | 5.20B | 7.73B | 7.88B | 6.65B | 2.37B | 5.33B | 5.73B | 3.67B | 4.84B | 5.95B |
| Income Before Tax Ratio | 11.51% | 23.21% | 23.11% | 7.42% | 25.33% | 15.87% | 27.39% | 30.75% | 29.07% | 11.87% | 28.38% | 31.15% | 21.03% | 30.92% | 41.86% |
| Income Tax Expense | 1.38B | 1.63B | 1.44B | -1.22B | 544.00M | -490.00M | 2.42B | 1.93B | 1.50B | 595.00M | 1.20B | 450.00M | 235.40M | 658.00M | 1.31B |
| Net Income | 4.86B | 11.84B | 11.54B | 4.62B | 7.88B | 5.69B | 5.31B | 5.95B | 5.14B | 1.77B | 4.13B | 5.28B | 3.43B | 4.18B | 4.64B |
| Net Income Ratio | 8.95% | 20.39% | 20.54% | 10.08% | 23.69% | 17.36% | 18.82% | 23.22% | 22.50% | 8.89% | 21.97% | 28.70% | 19.68% | 26.72% | 32.62% |
| EPS | 2.70 | 6.69 | 6.53 | 2.62 | 5.33 | 3.85 | 3.33 | 3.74 | 3.20 | 1.11 | 2.60 | 3.35 | 2.12 | 2.59 | 2.87 |
| EPS Diluted | 2.72 | 6.63 | 6.45 | 2.62 | 5.31 | 3.68 | 3.30 | 3.63 | 3.13 | 1.10 | 2.56 | 3.35 | 2.11 | 2.57 | 2.85 |
| Weighted Avg Shares Out | 1.79B | 1.77B | 1.77B | 1.77B | 1.48B | 1.48B | 1.59B | 1.59B | 1.61B | 1.59B | 1.59B | 1.58B | 1.62B | 1.62B | 1.62B |
| Weighted Avg Shares Out (Dil) | 1.77B | 1.78B | 1.78B | 1.77B | 1.48B | 1.55B | 1.60B | 1.63B | 1.64B | 1.61B | 1.60B | 1.58B | 1.63B | 1.63B | 1.63B |
Source: https://incomestatements.info
Category: Stock Reports